The Perils of FDA Postmarket Studies: Why Delayed Drug Research Leaves Patients and Payers in the Dark

The regulatory framework governing modern pharmaceuticals relies heavily on a delicate balancing act: accelerating access to lifesaving therapies for vulnerable patients versus ensuring long-term safety and efficacy through rigorous clinical validation. When the U.S. Food and Drug Administration (FDA) approves drugs or medical devices with limited pre-approval data, it frequently does so with a regulatory condition attached—mandating that the manufacturer conduct postmarket studies to evaluate hidden risks, long-term outcomes, and real-world efficacy. However, a systemic failure in follow-through has turned these mandated requirements into what critics call "toothless" suggestions, leaving patients, physicians, and health care payers navigating a dangerous void of uncertainty.

An extensive analysis of federal regulatory data reveals that hundreds of postmarket studies are currently running behind schedule. In many instances, these required investigations face delays spanning years or over a decade, while the manufacturers continue to market, distribute, and profit from the products. This enforcement gap places immense financial and physical burdens on the American healthcare system, raising urgent questions about regulatory oversight as administrative policy shifts push to further streamline drug approvals.

The Anatomy of Postmarket Delays: The Case of Tavneos

The risks inherent in relying on postmarket studies are sharply underscored by the trajectory of Tavneos (avacopan), a specialty medication approved by the FDA in 2021 to treat severe cases of ANCA-associated vasculitis, a group of rare and potentially fatal autoimmune diseases characterized by destructive inflammation of blood vessels and organs. Internal agency records indicate that when the drug was initially reviewed, FDA experts warned against approval, explicitly citing "limited safety data" provided by the manufacturer.

Overriding these internal reservations, the agency approved Tavneos with a binding proviso: Amgen, which later acquired the drug’s original developer ChemoCentryx, was required to conduct an extensive, years-long postmarket safety study involving 300 patients, each monitored for five years, to evaluate long-term safety signals—specifically including potential drug-induced liver injury.

Today, that mandated postmarket study is severely delayed. According to federal databases and regulatory filings, only a fraction of the required patient cohort has been successfully enrolled. Last year, the FDA noted that just 21 out of 300 targeted patients were participating, with Amgen later updating the figure to 49 enrollees amid recruitment hurdles. Company representatives have cited the availability of alternative treatments and patient reluctance to be randomized into placebo arms as primary drivers of the delay.

Meanwhile, real-world exposure to the drug has expanded significantly, with Amgen estimating global usage exceeding 25,000 patient-years. Concurrently, the FDA has identified dozens of cases of serious liver injury—the exact safety risk the postmarket study was designed to assess—"possibly" or "probably causally associated" with the medication. The regulatory standoff escalated dramatically when the FDA alleged that data from the original clinical trials submitted to secure approval had been manipulated, prompting the agency to initiate proceedings to withdraw Tavneos from the U.S. market. The European Union has already revoked its marketing authorization for the drug, though Amgen is contesting the U.S. withdrawal, maintaining that the product’s benefits outweigh its risks and that its data remain valid.

A Systemic Vulnerability: Hundreds of Delayed Studies

Tavneos is far from an isolated exception. Federal datasets track the progress of hundreds of postmarket requirements and commitments spanning conventional drugs, biologics, vaccines, and gene therapies. Out of thousands of tracked obligations, nearly 600 studies are officially listed as running behind schedule. Approximately a third of all ongoing postmarket evaluations are categorized as delayed, with more than 250 of those missing final report deadlines that were originally scheduled to be submitted years ago.

These delayed requirements encompass a wide array of high-profile medical products:

• The CustomFlex Artificial Iris: Approved in 2018 to replace damaged or missing irises in patients with rare conditions like aniridia, its mandated pediatric safety study was established with a protocol accepted in 2019. Years later, regulatory trackers showed zero patient enrollment due to the extreme rarity of the condition, forcing the manufacturer, distributor, and consultants to negotiate alternative monitoring pathways with the FDA.
• Paxlovid: Pfizer’s prominent antiviral treatment for COVID-19 missed its original deadline to complete a key post-approval study assessing safety profiles in pregnant women by the end of 2024. Pfizer has stated it is working collaboratively with the FDA to submit results as practicable.
• The Scandinavian Total Ankle Replacement (STAR) System: Approved alongside an initial clinical trial protocol in 2009, the mandated study aimed to enroll at least 500 subjects. Instead, it stalled at 142 participants, nearly half of whom experienced documented adverse events, including a high frequency of surgical revisions, reoperations, and device removals.
• Oxaydo: An abuse-deterrent formulation of oxycodone approved in 2011, which carried a mandate to evaluate whether it successfully reduced real-world misuse, overdose, and addiction. The final study report was scheduled for 2016, but the FDA issued a "failure to respond" letter in 2022. The product has since been discontinued as patents expired.

The Financial Incentive for Delay

For pharmaceutical and medical device manufacturers, operating with delayed postmarket studies carries minimal downside while preserving significant commercial advantages. Companies are permitted to continue selling their products at premium prices while postmarket obligations stall.

An influential 2022 investigation by the Department of Health and Human Services (HHS) Office of Inspector General revealed that public healthcare programs—specifically Medicare and Medicaid—spent more than $18 billion between 2018 and 2021 alone on drugs granted accelerated approval that had surpassed their original planned completion dates for confirmatory trials without finishing the required research.

High-profile cases illustrate the staggering financial stakes involved. Exondys 51 (eteplirsen), a treatment for Duchenne muscular dystrophy granted accelerated approval by the FDA in 2016 despite fierce internal dissent from agency scientists who warned it would offer "false hope" in exchange for unproven benefits, missed its May 2021 final postmarket report deadline. More than five years past that deadline, the study remained delayed due to recruitment challenges. Yet, during this extended period of validation limbo, the drug commanded annual price tags ranging from $750,000 to $1.5 million, generating over half a billion dollars in annual sales for manufacturer Sarepta Therapeutics.

Regulatory Realities and Policy Shifts

Federal health officials defend the post-approval ecosystem, emphasizing that delays can stem from legitimate operational hurdles such as patient recruitment difficulties, rare disease demographics, or complex clinical logistics. Emily Hilliard, a spokesperson for the Department of Health and Human Services, stressed that the existence of a study delay should not automatically be interpreted as evidence that a product harbors unresolved safety or efficacy issues, noting that the agency utilizes its enforcement authorities selectively and on a case-by-case basis.

However, independent medical researchers and health policy experts warn that upcoming policy shifts could place unprecedented strain on the post-approval framework. Recent initiatives by federal health leaders to streamline the regulatory process—such as establishing a "default requirement" of a single clinical trial instead of two for drug approvals, and rolling out ultra-fast expedited pathways like the Commissioner’s National Priority Voucher program—are designed to cut development costs and accelerate market entry.

While proponents argue these measures deliver crucial therapies to patients faster, critics contend that reducing pre-approval clinical scrutiny places an untenable burden on the postmarket system. Cardiologist Dr. Sanket Dhruva of the University of California-San Francisco noted that postmarket requirements have historically proven toothless. Similarly, Harvard Medical School professor Aaron Kesselheim cautioned that reducing upfront testing requirements inevitably increases the risk profile of newly approved products.

Broader Implications for Healthcare

The systematic lag in completing postmarket safety and efficacy studies creates a profound information vacuum for the American healthcare ecosystem. Physicians rely heavily on definitive clinical evidence to guide treatment decisions, and patients depend on verified safety profiles when putting their health and financial security on the line. When required studies languish for years or decades without completion, the medical community is left to practice in a fog of uncertainty.

As federal regulators continue to prioritize speed-to-market initiatives, the debate over accountability intensifies. Unless enforcement mechanisms for postmarket compliance are significantly strengthened, the burden of discovering whether an approved drug or medical device is genuinely safe and effective will continue to fall heavily on the patients who take them and the public programs that pay for them—long after the products have already reached commercial markets.